Suven Life Sciences enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
6,967————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
8.38.337.390.983.4
6,959————
−8.3−8.3−37.3−90.9−83.4
₹263.89————
591591110270375
789.58×————
−19.00×————
−18.67×————
Reference items — trailing FY values
8.87.16.711.713.5
−366−285−166−128−126
−373−290−172−135−132
—−302−154−82.6−208
−307−307−191−85.0−211
—−307−191−85.0−211
—5.137.32.42.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹6,967 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————6,967.5
- Cash, Equiv & ST Investments83.490.937.38.38.3
Enterprise Value————6,959.2
Net Debt (memo)-83.4-90.9-37.3-8.3-8.3
EV per Share————263.89
Total Capital375.3270.0110.0591.4591.4
EV/Sales————789.58
EV/EBITDA————-19.00
EV/EBIT————-18.67
Reference Items — Trailing FY Values
Sales13.511.76.77.18.8
EBITDA-125.9-128.0-165.8-284.5-366.3
EBIT-132.4-134.5-171.6-290.1-372.7
Operating Cash Flow-207.9-82.6-154.1-301.8—
Free Cash Flow-210.8-85.0-191.4-306.9-306.9
FCFF (free cash flow to the firm)-210.8-85.0-191.4-306.9—
Capital Expenditure2.92.437.35.1—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.